Editor's Corner

With just a little under two weeks to go, we're closing in on 200 registrants for the FierceBiotech webinar on October 27. If you have time available for the 2pm ET event with venture capitalists Steven Burrill, Sherrill Neff and Scott Minnick, along with Ernst & Young's Gil Forer, please make plans to join us. We'll be covering the key issues facing biotech companies that will be looking to raise funds in 2006. So if you're planning to raise a new round, or advise anyone who is, it should be well worth your time. You also can't beat the price. There's no charge to listen in. - John Carroll

Suggested Articles

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.

Getting lurbinectedin on the fast track tees the partners up to learn whether the FDA will approve the drug by mid-August.